Dr. Moore on the Results of the NOVA Trial in Ovarian Cancer

Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel ApproachesПодробнее

Design of the NOVA Trial for Ovarian CancerПодробнее

Dr. Moore on the Prevalence of Ovarian CancerПодробнее

Dr. Moore on the NOVA Trial for Ovarian CancerПодробнее

Treating Ovarian Cancer With Niraparib: The NOVA TrialПодробнее

Niraparib Maintenance for Recurrent Ovarian CancerПодробнее

Dr. Moore on the Role of Mirvetuximab Soravtansine in Ovarian CancerПодробнее

Dr. Moore on Early-Phase Data With Mirvetuximab Soravtansine in Ovarian CancerПодробнее

Dr. Moore on Results of the FORWARD I/GOG 3011 Trial in Ovarian CancerПодробнее

Results from the ENGOT-OV16/NOVA trial: efficacy and safety of niraparib in ovarian cancerПодробнее

Dr. Matulonis on the NOVA Trial of Niraparib Maintenance Therapy in Ovarian CancerПодробнее

Final Overall Survival Results From the Phase 3 SOLO2 Trial for Ovarian CancerПодробнее

Dr. Moore Discusses Combinations in Ovarian CancerПодробнее

Overview of ENGOT-OV16/NOVA of niraparib in ovarian cancer and why the results were not surprisingПодробнее

Dr. Moore on the Impact of SOLO-1 in Ovarian CancerПодробнее

Results from phIII SOLO1 trial in BRCAm ovarian cancerПодробнее

Dr. Mirza on the Phase III NOVA Trial in Ovarian CancerПодробнее

Dr. Moore on Unanswered Questions With PARP Inhibitors in Ovarian CancerПодробнее

Dr. Moore on Challenges With Immunotherapy in Ovarian CancerПодробнее

Challenges With PARP Inhibitors in Ovarian CancerПодробнее